Table 1.

Dose-escalation and dose-limiting toxicities

Dose levelIpilimumab IV q 28 days x 4Lenalidomide PO daily x 21 q 28 days until disease progressionNumber of patients (patients evaluable for DLT)DLT event
11.5 mg/kg10 mg4 (3)
21.5 mg/kg15 mg11 (8)G3 rash, G3 pancreatitis
33 mg/kg15 mg8 (6)G3 rash
43 mg/kg20 mg5 (4)
53 mg/kg25 mg8 (7)G3 rash